Fu Ming-Sheng, Pan Shu-Xian, Cai Xun-Quan, Hu Yuan-Xin, Zhang Wei-Jie, Pan Qin-Cong
Department of Gastroenterology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Department of Nephrology of Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Front Oncol. 2022 Jun 27;12:899837. doi: 10.3389/fonc.2022.899837. eCollection 2022.
This study aims to analyze the correlation between ARHGAP4 in the expression and clinical characteristics of colorectal cancer (CRC), and the influence of ARHGAP4 expression on the prognosis of CRC, and to evaluate whether ARHGAP4 is a potential prognostic oncotarget for CRC.
ARHGAP4 was identified using the Gene Expression Omnibus database through weighted gene coexpression network analysis. Using the Gene Expression Profiling Interactive Analysis to perform and analyze the expression and prognosis of ARHGAP4 in CRC. The expression of AGRGAP4 and immune cells was analyzed by the Tumor IMmune Estimation Resource online database. Finally, immunohistochemistry was used to analyze the expression difference and prognosis of ARHGAP4 in CRC and adjacent normal tissues, as well as the relationship between AGRGAP4 expression and clinical features of CRC.
We identified ARHGAP4 that is related to the recurrence of CRC from GSE97781 data. ARHGAP4 has not been reported in CRC. The high expression of ARHGAP4 in select colon adenocarcinoma indicates a poor prognosis by database analysis. In our clinical data results, ARHGAP4 is highly expressed in CRC and lowly expressed in normal tissues adjacent to cancer. Compared with the low-expression group, the high-expression group has a significantly poorer prognosis. In colon cancer, the B-cell, macrophage, neutrophil, and dendritic-cell levels are downregulated after ARHGAP4 gene knockout; the levels of CD8 and CD4 T cells, neutrophils, and dendritic cells are upregulated after the amplification of the ARHGAP4 gene. In addition, ARHGAP4 expression is related to N,M staging and clinical staging.
ARHGAP4 is highly expressed in CRC, and the high expression of ARHGAP4 has a poor prognosis. The expression of ARHGAP4 in CRC is related to the immune cells such as B cells, CD8 and CD4 T cells, macrophages, neutrophils, and dendritic cells. ARHGAP4 is correlated with N,M staging and clinical staging in CRC. ARHGAP4 may be a potential biomarker for the prognosis of CRC.
本研究旨在分析ARHGAP4表达与结直肠癌（CRC）临床特征之间的相关性，以及ARHGAP4表达对CRC预后的影响，并评估ARHGAP4是否为CRC潜在的预后癌靶标。
通过加权基因共表达网络分析，利用基因表达综合数据库鉴定ARHGAP4。使用基因表达谱交互式分析来进行并分析ARHGAP4在CRC中的表达及预后。通过肿瘤免疫估计资源在线数据库分析AGRGAP4与免疫细胞的表达。最后，采用免疫组织化学分析ARHGAP4在CRC及癌旁正常组织中的表达差异及预后，以及AGRGAP4表达与CRC临床特征的关系。
我们从GSE97781数据中鉴定出与CRC复发相关的ARHGAP4。ARHGAP4在CRC中尚未见报道。通过数据库分析，在部分结肠腺癌中ARHGAP4高表达提示预后不良。在我们的临床数据结果中，ARHGAP4在CRC中高表达，在癌旁正常组织中低表达。与低表达组相比，高表达组预后明显更差。在结肠癌中，ARHGAP4基因敲除后B细胞、巨噬细胞、中性粒细胞和树突状细胞水平下调；ARHGAP4基因扩增后CD8和CD4 T细胞、中性粒细胞和树突状细胞水平上调。此外，ARHGAP4表达与N、M分期及临床分期相关。
ARHGAP4在CRC中高表达，其高表达预后不良。ARHGAP4在CRC中的表达与B细胞、CD8和CD4 T细胞、巨噬细胞、中性粒细胞和树突状细胞等免疫细胞相关。ARHGAP4与CRC的N、M分期及临床分期相关。ARHGAP4可能是CRC预后的潜在生物标志物。
